Epistem, the Manchester based biotech and personalised medicine developer, announced a Tuberculosis diagnostic collaboration with Xcelris Laboratories, one of India’s leading Genomics research and Diagnostic testing companies. India has the largest number of TB sufferers in the world with 2 million patients developing TB every year, of which around half a million cases are fatal.
Epistem and Xcelris will be evaluating Epistem’s Genedrive in identifying and diagnosing the infection at an early stage.
The EHP share price has increased by 10% over the last year.
Epistem Holdings Plc is currently graded b by LCF Research. To learn more, follow this link.
